Key clinical point: CD123 may be considered as a cardinal marker for residual disease assessment and response evaluation in AML and B-ALL.
Major finding: CD123 expression was associated with MRD positive status in both B-ALL (P < .001) and AML (P = .001).
Study details: A total of 757 samples of acute leukemia including 479 treatment naive and 278 follow-up samples were compared.
Disclosures: The authors reported that they had no conflicts of interest.
Das N et al. Clin Lymphoma Myeloma Leuk. 2020 May 10; doi.org/10.1016/j.clml.2020.05.004.